Autoantigen-Specific Treg Expansion for Suppressive Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for treating autoimmune diseases with regulatory T cells are limited by their low abundance in human peripheral blood mononuclear cells and inadequate expansion techniques, leading to insufficient therapeutic efficacy.
Innovation Solution
A method for ex-vivo expansion of CD4+CD25+ regulatory T cells using an autoantigen-specific stimulatory composition, comprising a TCR/CD3 activator and a co-stimulator like IL-2, immobilized on a solid surface, achieving a 100 to 1,000-fold expansion with enhanced suppressive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Tregs are used for treatment of autoimmune diseases, then therapeutic effects are achieved, but the low abundance of Tregs in peripheral blood limits their availability for therapy
Solution Approach 1:
The patent applies preliminary action by expanding Tregs ex-vivo before administration to patients. The method activates and proliferates Tregs in culture using autoantigen-specific stimulatory compositions, thereby preparing sufficient quantities of therapeutic cells in advance. This resolves the contradiction by generating adequate Treg numbers prior to clinical use, overcoming the naturally low abundance in peripheral blood.
Solution Approach 2:
The patent employs parameter changes by modifying the activation and proliferation parameters of Tregs through specific cultural conditions. By optimizing stimuli (autoantigen-specific compositions), cytokines (IL-2), and culture duration, the method transforms a small number of input Tregs into large numbers of expanded cells with enhanced suppressive function, thereby resolving the quantity limitation.
2Quantity of substance
If conventional expansion methods are used, then Treg numbers increase, but the suppressive function of expanded Tregs is insufficient
Solution Approach 1:
The patent applies local quality by providing different stimuli to different subsets of Tregs based on their autoantigen specificity. The method uses autoantigen-specific stimulatory compositions that selectively activate and expand Tregs recognizing particular autoantigens while maintaining their disease-specific suppressive functions. This ensures that expanded Tregs retain localized, disease-relevant suppressive capabilities rather than generic proliferation.
Solution Approach 2:
The patent employs feedback mechanisms by using autoantigen-specific stimulatory compositions that selectively expand Tregs with appropriate specificity. The method incorporates selection pressures during expansion that favor Tregs capable of recognizing disease-relevant autoantigens, thereby ensuring that the expanded population maintains enhanced suppressive function targeted at the specific autoimmune condition.
3Quantity of substance
If Tregs are activated and expanded ex-vivo, then sufficient quantities are obtained for therapy, but complex expansion protocols are required
Solution Approach 1:
The patent applies universality by using a multi-functional stimulatory composition that simultaneously provides TCR/CD3 activation, co-stimulation, and cytokine support in a single system. The autoantigen-specific composition works across different autoimmune diseases and patient populations, providing a universal platform for Treg expansion that simplifies the protocol while achieving high fold-expansion and functional retention.
Data Source
AI summary
The invention provides methods for the ex-vivo expansion of CD4+CD25+ Tregs. The invention provides a method for producing ex vivo expanded Tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens. Additionally, the ex vivo expanded Tregs may provide treatment for inflammatory/autoimmune diseases.